Series AAA Investors

Advanced Accelerator Applications (AAA), a Novartis company, is a leader in the field of Molecular Nuclear Medicine (MNM). The company specializes in the development and commercialization of radiopharmaceuticals for both diagnostic and therapeutic purposes, particularly in oncology. Its flagship product, Lutathera, is a first-in-class peptide receptor radionuclide therapy (PRRT) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. AAA also markets Netspot and Somakit TOC for the localization of these tumors using PET imaging. Following its acquisition by Novartis in 2018, the company has continued to expand its pipeline, focusing on targeted radioligand therapies for various cancers, including prostate cancer.